Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases.
Germany's Federal Joint Committee (G-BA) grants LOJUXTA® (lomitapide) hard capsules a "no additional benefit" assessment based upon technical matters within the value dossier submitted. As expected, the decision is consistent with G-BA's preliminary assessment granted in March of this year. The Company plans to re-submit the dossier following the expiration of the decision on June 15, 2015.
5.6.14 - Aegerion Pharmaceuticals Announces First-Quarter 2014 Financial Results
4.9.2014 - Aegerion Pharmaceuticals Initiates Phase 3 Clinical Trial in Japan to Evaluate Lomitapide for Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
2013 Annual Report
© 2012 Aegerion Pharmaceuticals, Inc. All rights reserved. AEGR/Global/167 07-14